Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3728 in Advanced Solid Tumors and Hematologic Tumors
NCT04523285Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3728 in solid tumor and hematologic neoplasm, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Maximum tolerated dose at 28 days. Status: unknown.
02
Drugs
TQB3728
03
Conditions
solid tumorhematologic neoplasm
Beyond the preview
Go deeper on NCT04523285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523285.